

1 **S100A8/A9 mediate the reprogramming of normal mammary epithelial cells
2 induced by dynamic cell-cell interactions with adjacent breast cancer cells.**

3

4 Seol Hwa Jo (cho5761@hanmail.net)¹, Woo Hang Heo (woohang92@gmail.com)¹,
5 Bok Sil Hong (boksil427@gmail.com)², Ju Hee Kim (jhsbzr@naver.com)², Jiwoo
6 Lee (leehy69@snu.ac.kr)², Eun-Shin Lee (silvershoe99@gmail.com)³, Han-Byoel Lee
7 (hblee80@gmail.com)³, Wonshik Han (hanw@snu.ac.kr)^{2,3,4}, Yeonju Park
8 (pyj11@snu.ac.kr)⁵, Dong-Sup Lee (dlee5522@snu.ac.kr)⁵, Nam Hoon Kwon
9 (nanarom1@snu.ac.kr)⁶, Min Chul Park (minchul.park@neomics.com)⁶, Jeesoo Chae
10 (moverm0210@gmail.com)^{4,7}, Jong-II Kim (jongil@snu.ac.kr)^{4,7}, Dong-Young Noh
11 (dynoh@snu.ac.kr)^{3,4,8}, Hyeong-Gon Moon (moonhg74@snu.ac.kr)^{2,3,4}.

12

13 ¹Interdisciplinary Graduate Program in Cancer Biology, Seoul National University
14 College of Medicine, Seoul, Korea,

15 ²Center for Medical Innovation, Biomedical Research Institute, Seoul National
16 University Hospital, Seoul, Korea,

17 ³Department of Surgery, Seoul National University College of Medicine, Seoul, Korea,

18 ⁴Genomic Medicine Institute, Medical Research Center, Seoul National University
19 College of Medicine, Seoul, Korea,

20 ⁵Department of Biomedical Sciences, Seoul National University College of Medicine,
21 Seoul, Korea,

22 ⁶Medicinal Bioconvergence Research Center, Seoul National University, Suwon, Korea,

23 ⁷Department of Biochemistry, Seoul National University College of Medicine, Seoul,
24 Korea

25 ⁸Cancer Research Institute, Seoul National University College of Medicine, Seoul,
26 Korea

27

28 **Address correspondence to:**

29 Dong-Young Noh, Seoul National University College of Medicine, 103 Daehak-ro,
30 Jongno-gu, Seoul, 03080, South Korea. Phone: 82-2-2072-2772; Fax: 82-2-766-3975;
31 E-mail: dynoh@snu.ac.kr

32

33 Hyeong-Gon Moon, Seoul National University College of Medicine, 103 Daehak-ro,
34 Jongno-gu, Seoul, 03080, South Korea. Phone: 82-2-2072-2634; Fax: 82-2-766-3975;
35 E-mail: mooonhg74@snu.ac.kr

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54 **Abstract**

55

56 **Background:** Tumor microenvironment drive the progression of solid tumors. Among
57 the various cell types in the breast cancer microenvironments, non-tumorigenic
58 mammary epithelial cells are often located in the vicinity of malignant cancer cells.
59 However, the biologic characteristics of non-tumorigenic mammary epithelial cells
60 adjacent to breast cancer cells are poorly understood.

61 **Methods:** Non-tumorigenic mammary epithelial MCF10A cells were co-cultured with
62 various breast cancer cells and the extent of cell-cell interactions was evaluated by
63 time-lapse imaging. The molecular and functional traits of the co-cultured MCF10A
64 cells were investigated by using RNA sequencing, phosphor-protein arrays, pathway
65 analysis, and various *in vitro* assays. The molecular changes observed in vitro were
66 validated using breast cancer xenograft mouse models. The phenotype changes in the
67 S100A8/A9-overexpressing MCF10A cells were investigated to determine the causal
68 relationship of S100A8/A9 upregulation observed in co-cultured MCF10A cells.

69 **Results:** When the cells were co-cultured directly, there were dynamic cell-cell
70 interactions between the MCF10A cells and breast cancer cells including lamellipodia-
71 or nanotube-like contacts and transfer of extracellular vesicles. MCF10A cells exhibited
72 features of epithelial-mesenchymal transition, and showed increased capacity of cell
73 proliferation, migration, colony formation, and 3-dimensional sphere formation upon the
74 direct co-culture with breast cancer cells. Transcriptome analysis and phosphor-protein
75 array suggested that several cancer-related pathways are significantly dysregulated in
76 MCF10A cells after the direct co-culture with breast cancer cells. S100A8/A9 showed
77 distinct up-regulation in the co-cultured MCF10A cells and orthotropic xenograft of
78 syngeneic mouse mammary tumors. When S100A8/A9 overexpression was induced in

79 MCF10A cells, the cells showed phenotypic features of directly co-cultured MCF10A
80 cells in terms of *in vitro* cell behaviors and signaling activities.

81 **Conclusions:** This study suggests the possibility of dynamic cell-cell interactions
82 between non-tumorigenic mammary epithelial cells and breast cancer cells that could
83 lead to a substantial transition of molecular profiles and functional characteristics in
84 mammary epithelial cells. S100A8/A9, along with other dysregulations in cancer-
85 related signaling pathways, may mediate this phenotype transition of non-tumorigenic
86 mammary epithelial cells.

87

88 Keywords: Breast cancer, Mammary epithelial cells, Microenvironment, Cell-cell
89 interaction, S100A8/A9, mTOR

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106 **Backgrounds**

107

108 In solid tumors, the complex tumor microenvironment controls all steps of tumor
109 progression and metastasis [1, 2]. The tumor microenvironment is comprised of various
110 endogenous and recruited cells that undergo dynamic cell-cell interactions with
111 malignant epithelial cells and contribute to the tumor cell's behaviors [3, 4]. For
112 example, cancer-associated fibroblasts actively remodel extracellular matrix and
113 immune microenvironment, and cancer-associated adipocytes provide inflammatory
114 milieu that support tumor growth [5, 6]. Moreover, recent efforts to target the immune
115 microenvironment have shown promising therapeutic responses in selected solid
116 tumors [7]. Therefore, understanding the molecular mechanisms of the tumor-
117 microenvironment interactions can provide scientific basis for developing novel
118 therapeutic strategies that target the tumor microenvironment [3, 8, 9].

119 Normal epithelial cells are closest neighbors to the malignant transformed cells in
120 human epithelial tumors arising from solid organs. During the early steps of
121 carcinogenesis, the normal epithelial cells may exert tumor-suppressive effects by
122 promoting protrusion of transformed epithelial cells from the epithelial layers [10-12].
123 However, the tumor-suppressive effects of normal epithelial cells may not last
124 throughout the solid tumor progression. While the normal myoepithelial cells obtained
125 from healthy human breast tissues contribute to the maintaining polarity of mammary
126 epithelial cells and suppress aberrant growth, the myoepithelial cells derived from
127 breast cancer tissues failed to restore physiologic polarity in mammary epithelial cells
128 and showed increased expression of various chemokines such as CXCL12 [13, 14].
129 These reports suggest a potential functional transition of normal epithelial cells caused
130 by adjacent malignant epithelial cells which may contribute the progression of solid

131 tumors.

132 In this study, we show that breast cancer cells and non-tumorigenic mammary epithelial
133 cells undergo dynamic cell-cell interactions that lead to a substantial reprogramming of
134 molecular characteristics of the mammary epithelial cells. The reprogramming of normal
135 mammary epithelial cells includes phenotypes changes as well as dysregulations of
136 mRNA expression and cell signaling activities. Our data suggests that S100A8/A9
137 upregulation in non-tumorigenic mammary epithelial cells may play a critical role in the
138 phenotype shifting induced by adjacent cancer cells.

139

140

141 **Methods**

142

143 **Cell culture**

144 Cells were purchased from Korean Cell Line Bank (Seoul, Korea). Non-tumorigenic
145 mammary epithelial MCF10A cells were maintained in a 1:1 mixture of Dulbecco's
146 Modified Eagle's Medium (DMEM) and Ham's F12 medium (F12) with 5% horse serum,
147 20 ng/mL epidermal growth factor (EGF), 100 ng/mL cholera toxin, 10 µg/mL insulin,
148 and 500 ng/mL hydrocortisone. MCF7 and MDA-MB-231 breast cancer cells were
149 cultured in DMEM with 10% FBS, 1% penicillin, and 1% streptomycin. SK-BR3 breast
150 cancer cells were cultured in RPMI 1640 with 10% FBS, 1% penicillin, and 1%
151 streptomycin. For fluorescence tagged cells, puromycin was added.

152

153 **Co-culture of MCF10A cells and breast cancer cells**

154 To optimize the culture medium for co-culture, we tested the effect of various mixture of
155 MDA-MB-231 culture media and MCF10A culture media on cell survival. Based on the
156 effect on cell proliferation, we chose 7:3 ratio mixture of MDA-MB-231 media and
157 MCF10A media for the direct co-culture of the cells (Additional File 1). For effective
158 separation of MCF10A cells and MDA-MB-231 cells after the direct co-culture, MCF10A
159 cells and MDA-MB-231 cells were transfected with GFP and RFP using lentiviral
160 vectors, respectively. After the direct co-culture, cells were isolated using a FACS Aria II
161 cell sorter (Becton Dickinson, NJ) as shown in the Additional File 2.
162 Indirect co-culture was performed by using transwell inserts (pore size 0.4um). Cancer
163 cells were seeded on the membrane of the insert and MCF10A cells were seeded on
164 the bottom six well plates. For controls, same cells were seeded in the bottom wells
165 and on the transwell inserts.

166

167 ***In vitro assays measuring cell phenotypes***

168 Proliferation assays were conducted using CellTiter-Glo Luminescent Cell Viability
169 Assay (Promega, Madison, USA) following the manufacturer's protocol. Cells were
170 seeded in triplicate into 96-well plates at a density of 2,000 cells per well. For migration
171 assay, 2×10^4 cells were seeded in an insert (8 μ m pore size) with serum free media and
172 media with 10% FBS was added in lower chambers. Cells were incubated for 20hrs
173 and fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. For colony
174 formation assay, 2×10^3 cells were seeded into 6-well plates. After 2 weeks, colonies
175 were fixed in 4% paraformaldehyde and stained with 0.1% crystal violet.

176

177 **RNA Sequencing and qPCR**

178

179 RNA sequencing libraries were prepared using TruSeq RNA Access library kit (Illumina,
180 Inc., San Diego, CA, USA) according to the manufacturer's protocol. After validation of
181 the libraries, using Agilent DNA screentape D1000 kit on a TapeStation (Agilent
182 Technologies, Santa Clara, CA, USA), the hybridization steps were performed using
183 exome capture probes and streptavidin coated beads. RNA sequencing was performed
184 by HiSeq 2000 (Illumina, San Diego, USA by the Macrogen Incorporated). We
185 processed reads from the sequencer and aligned them to the Homo sapiens (hg19).
186 After aligning reads to genome, Cufflinks v2.2.1 was used to assemble aligned reads
187 into transcripts and to estimate their abundance. The transcript counts in isoform and
188 gene level were calculated, and the relative transcript abundances were measured in
189 FPKM (Fragments Per Kilobase of exon per Million fragments mapped) from Cufflinks.
190 RNA sequencing data of breast cancer was generated through a separate project to
191 characterize the genomic profiles of the primary breast tumor and patient-derived
192 xenograft tumors which will be presented in other reports (IRB No. 1402-054-555).

193 For qPCR, total RNA was extracted from isolated cells with TRIzol (Favorgen, Taiwan).
194 PrimeScript 1st strand cDNA Synthesis Kit (Takara, Japan) were used for reverse
195 transcription of RNA, and resulting cDNA was amplified using Power SYBR® Green
196 PCR Master Mix (Applied Biosystems, CA). The information on the primer sequences
197 used in this study is listed in the Additional File 3.

198

199 **Phosphorylation array and western blotting**

200

201 For phosphorylation array, protein extraction was done with buffer following the
202 manufacturer's protocol. Protein concentration was measured by BCA assay kit
203 (Thermo scientific, Palm Springs, CA, USA). Phosphorylation array was performed by
204 using the human phosphor-kinase array kit (R&D systems, USA).

205 Proteins were harvested with RIPA buffer (Thermo scientific, Palm Springs, CA, USA),
206 protease & phosphatase inhibitor and 0.5M EDTA solution. Protein concentration was
207 measured by BCA assay kit (Thermo scientific, Palm Springs, CA, USA). Cell lysates
208 were loaded onto 10% gels and transferred to a PVDF membrane. The membrane was
209 blocked with 5% skim milk and incubated with primary antibody overnight at 4°C. The
210 peroxidase-conjugated secondary antibody was used for detection. Bands were
211 detected by LAS. The information on the antibodies used in this study is listed in the
212 Additional File 4.

213

214 **Cell imaging**

215

216 For time-lapse imaging of cells during the direct co-culture, 9x10³ GFP-transfected
217 MCF10A cells and 2x10⁴ RFP-transfected MDA-MB-231 cells were seeded in 8-well

218 chambers and cultured for 24 hours. After 24 hours culture, live cells images were
219 taken every 10 minutes with fixed position for 16 hours by using Leica confocal
220 microscope (Leica TCS SP8, Leica Microsystems Ltd, Korea), and the obtained images
221 were analyzed by Leica LAS X program.

222 For *in vivo* imaging, the experiments were performed in accordance with the Animal
223 Care and Use Committee guidelines of Woosung BSC (Suwon, Korea). Hair-removed
224 ear skin of C57BL/6 mouse (10 weeks old) was injected with 4.6×10^4 cells of the
225 mixture MCF10A-GFP (2.3×10^4) and MDA-MB-231-RFP (2.3×10^4) cell lines. The
226 mice were anesthetized with an intraperitoneal injection of Zoletil (30 mg/kg, Virbac,
227 Carros, France) and Rompun (10 mg/kg, Bayer-Korea, Seoul, Korea) before imaging.
228 The mice were placed on the heated plate of a motorized XYZ translational stage. The
229 *in vivo* movement of MCF10A and MDA-MB-231 was monitored by modified custom-
230 built laser-scanning confocal microscopy {Choe, 2015 #3}. GFP-expressing cells were
231 visualized at an excitation wavelength of 491 nm and detected through a bandpass
232 filter of 502 nm to 537 nm (Semrock Inc, Rochester, NY, USA). RFP-expressing cells
233 were imaged at an excitation wavelength of 532 nm and detected using a bandpass
234 filter of 562 nm to 596 nm (Semrock Inc). Cell movement was visualized at 1 min
235 interval for 2 hr. After acquired from the imaging system, 512 x 512 pixel images were
236 then compensated with Matlab (Mathworks, Natick, MA, USA) and reconstructed by
237 ImageJ software.

238

239 **S100A8/A9 expression in xenograft tumor-bearing mouse fatpad**

240

241 5-week-old BALB/c mice were purchased from KOATECH (Seoul, Korea) and housed
242 in Seoul National University Hospital Clinical Research Institute's Specific Pathogen
243 Free zone. All experiments were approved by the Institutional Animal Care and Use

244 Committee in Seoul National University Hospital (SNUH-IACUC, 17-0165-S1A0 (1)). To
245 obtain control mouse fatpads, eight-week-old non-tumor-bearing BALB/c mouse was
246 sacrificed and mammary fat pad was resected. To obtain tumor-bearing mouse fat pad,
247 2×10^5 4T1 mouse mammary epithelial cancer cells were injected in 6-week-old
248 BALB/c mouse's mammary fat pad. At two weeks after the tumor injection, the mouse
249 was sacrificed and tumor-bearing mammary fatpad was resected. The resected fatpads
250 were fixed with 4% PFA and embedded in paraffin.

251

252 **S100A8/A9-overexpressing MCF10A cell line**

253

254 The coding sequences of S100A8 and S100A9 were acquired by RT-PCR and cloned
255 into pCDH-GFP and pCDH-RFP vectors. MCF10A cells were transfected with lentivirus
256 S100A8-GFP and S100A9-RFP construct. Transfected cells were selected by
257 puromycin.

258

259 **Statistical analysis**

260

261 In general, most data represent the mean \pm S.D and are representative of 3
262 independent experiments, except for RNA sequencing and phospho-protein arrays
263 which are two independent experiments. Graph Pad Prism (ver. 7.01) was used for
264 generating graphs and heatmaps and performing statistical tests. P values were
265 calculated from unpaired two-tailed Student's t tests or Mann-Whitney test as
266 appropriate.

267 To identify differentially expressed genes, we filtered genes with one more than zeroed
268 FPKM values and the data were log2-transformed and subjected to quantile
269 normalization. Statistical significance of the differential expression data was determined

270 using fold change in which the null hypothesis was that no difference exists among
271 samples. Gene pathway analysis for the DEG was done based on KEGG pathway
272 (<http://www.genome.jp/kegg/pathway.html>).

273

274

275

276

277

278 **Results**

279

280 **Breast cancer cells show dynamic cell-cell interactions with non-transformed**
281 **mammary epithelial cells *in vitro* and *in vivo*.**

282

283 First, we determined the presence and the extent of cell-cell interactions *in vitro*
284 between the breast cancer cells and mammary epithelial cells. We co-cultured the
285 RFP-transfected breast cancer cells (MDA-MB-231) with GFP-transfected non-
286 transformed mammary epithelial cells (MCF10A) using *in vitro* direct co-culture method.

287 While the majority of MCF10A cells maintained the clusters of adherent cells, MDA-MB-
288 231 cells showed spreading patterns of cell growth and the cells infiltrated between the
289 MCF10A cell clusters (Additional File 5). The time-lapse imaging of the cells showed
290 that MDA-MB-231 cells had more frequent cell movements than the MCF10A cells and
291 the cells showed various dynamic cell-cell interaction patterns (Additional File 6 and 7).

292 MDA-MB-231 cells formed both lamellipodia-like structures for adjacent cells and
293 nanotube-like projections for long-range cell-cell interactions (Figure 1a and 1b,
294 Additional File 5) [15, 16]. The lamellipodia-like structures of MDA-MB-231 cells
295 actively contacted the MCF10A cells and a portion of extended lamellipodia could
296 remain as extracellular vesicles which were then engulfed by adjacent MCF10A cells
297 (Figure 1c, Additional File 7).

298 Among the various cell-cell interactions, exchanges of extracellular vesicles were
299 frequently seen between the cells. MCF10A cells engulfed extracellular vesicles
300 originated from MDA-MB-231 cells, and the vesicles were often transferred to the
301 nucleus while some stayed at cytoplasm (Figure 1d and 1e). Additionally, a small
302 proportion of co-cultured cells (1~2%) exhibited mixed fluorescence (Figure 1f,
303 Additional File 2).

304 To observe the cell-cell interactions *in vivo*, we inoculated a mixture of MDA-MB-231
305 cells and MCF10A cells in the earlobes of nude mouse and obtained the time-lapse
306 imaging data. After one hour of the inoculation, the movements of the MDA-MB-231
307 cells around the MCF10A cells were detectable (Additional File 8 and 9). After 24 hours,
308 the cell-cell interactions and exchange of vesicles were more frequently seen between
309 the cells (Figure 1g, Additional File 9). These data suggest that the cancer cells and
310 epithelial cells can undergo a dynamic range of physical contacts and cell-cell
311 interactions both *in vitro* and *in vivo*.

312

313 **Direct co-culture with breast cancer cells induce phenotypic changes in MCF10A
314 cells**

315

316 We then determined whether the cell-cell interactions with breast cancer cells induce
317 phenotype changes in MCF10A cells. First, we co-cultured MCF10A cells with breast
318 cancer cell lines using in-direct co-culture system. MCF10A cells co-cultured indirectly
319 with cancer cells showed no significant changes in cell morphology or the cell growth
320 patterns in 2D and 3D cultures (Additional File 10). However, when the MCF10A cells
321 were cultured in the direct co-culture system with breast cancer cells, the MCF10A cells
322 showed substantial phenotypic changes. Directly co-cultured MCF10A cells, sorted by
323 GFP-expression, showed changes in cell morphology such as transition into spindle-
324 shaped cells and loss of cell-cell adhesions (Figure 2a).

325 Additionally, the MCF10A cells showed marked decrease in E-cadherin expression
326 when they were directly co-cultured with MDA-MB-231 cells (Figure 2b). When the
327 isolated MCF10A cells were grown *in vitro*, the proliferation rate, colony formation
328 capacity, and the cell migration ability were significantly enhanced in cells directly co-
329 cultured with MDA-MB-231 cells (Figure 2c-2e). MCF10A cells also showed higher

330 numbers and larger sizes of cell spheres when they were grown in 3D matrigels
331 (Figure 2f). Collectively, our data show that direct co-culture with breast cancer cells
332 induce substantial phenotype changes in non-tumorigenic mammary epithelial cells.

333

334 **Transcriptome changes and pathway dysregulations in MCF10A cells when**
335 **directly co-cultured with MDA-MB-231 cells**

336

337 To understand the molecular mechanisms underlying the phenotype changes induced
338 by direct co-culture, we analyzed the transcriptome profiles of MCF10A cells when they
339 were directly co-cultured with MDA-MB-231 cells. A total of 151 genes were
340 dysregulated in directly co-cultured MCF10A cells more than two-fold in expression
341 (Figure 3a, Additional File 11). Again, we observed the decreased expression of
342 mammary epithelial differentiation markers such as CDH1 or CD24. Based on the gene
343 expression profiles, we identified several cancer-related pathways, including metabolic
344 pathway, cell adhesion, growth factor signaling, and TP53 pathway, that were
345 significantly dysregulated in MCF10A cells after the direct co-culture (Figure 3b).

346 To determine the changes in the cell signaling in MCF10A cells when the cells were
347 directly co-cultured with MDA-MB-231 cells, we used the phosphorylation antibody
348 array to profile the phosphor-protein signaling pathways. Many of the candidate
349 phosphor-proteins showed differential levels of expression in the directly co-cultured
350 MCF10A cells. PRAS40, STAT6, ERK1/2 levels were substantially increased while
351 HSP60, β-catenin, RSK1/2/3, STAT3, and p53 levels were downregulated (Figure 3c).
352 These results suggest that non-tumorigenic mammary epithelial cells undergo a
353 significant shift in transcriptomic and proteomic characteristics.

354

355 **S100A8/A9 induction in peritumoral mammary epithelial cells and stromal**

356 **tissues**

357

358 Among the differentially expressed genes, S100A8 and S100A9 genes were highly
359 upregulated in directly co-cultured MCF10A cells and their increased expression was
360 validated in mRNA and protein levels (Figure 3a and 4a). When S100A8 and S100A9
361 mRNA levels in normal breast and breast cancer tissues were examined using RNA
362 sequencing data comprised of 65 normal and 68 cancer tissues, both genes were
363 significantly upregulated in breast cancer tissues when compared to normal breast
364 tissues (Figure 4b). Furthermore, the mRNA dataset from Finak et al [17] showed that
365 S100A8 and S100A9 genes were significantly upregulated in the adjacent stroma
366 tissues in human breast cancer (Figure 4c).

367 We then used mouse mammary carcinoma xenograft model to determine whether the
368 induction of S100A8/A9 expression by breast cancer cells also occurs *in vivo*. BALB/c
369 mouse fatpads were injected with 4T1 murine mammary carcinoma cells and were
370 subsequently harvested. Compared to non-tumor bearing fatpads, mouse mammary
371 epithelial cells and peritumoral stromal cells showed increased expression of both
372 S100A8 and S100A9 (Figure 4d and 4e). These findings in addition to the above
373 transcriptome data indicate that breast cancer cells induce S100A8/9 expression in
374 tumor microenvironment especially in non-tumorigenic mammary epithelial cells.

375

376 **S100A8/A9 upregulation contribute to the phenotypic and molecular changes in
377 the co-cultured MCF10A cells**

378

379 To determine the functional importance of S100A8 and S100A9 gene expression in
380 mammary epithelial cells, we established a stable MCF10A cells that overexpress
381 S100A8 and S100A9 genes. Transduction of S100A8 overexpression vector resulted in

382 upregulation of both S100A8 and S100A9 proteins (Additional File 12). S100A8-
383 overexpressing MCF10A cells showed higher rate of cell proliferation when compared
384 to the control cells (Figure 5a). Furthermore, S100A8-overexpressing MCF10A cells
385 showed increased cell migration, invasion, colony formation, and 3-dimensional cell
386 growth which are characteristics of the MCF10A cells directly co-cultured with breast
387 cancer cells. (Figure 5b-5d).

388 To investigated the effect of S100A8 and S100A9 expression on the signaling pathway
389 activities, we repeated the phosphorylation antibody array in S100A8-overexpressed
390 MCF10A cells (Figure 5e-5f). More than half of the signaling proteins observed in
391 S100A8-overexpressed MCF10A cells showed concordant expression patterns with
392 directly co-cultured MCF10A cells and only one protein showed opposite expression
393 pattern between the two cells (Figure 5g). The dysregulation of signaling pathways in
394 both S100A8 overexpressing MCF10A cells and the MCF10A cells directly co-cultured
395 with MDA-MB-231 cells were further validated using western blotting as shown in
396 Figure 5h. Taken together, our data demonstrate that, at least in part, the phenotypic
397 and molecular transitions seen in the mammary epithelial cells when co-cultured with
398 breast cancer cells can be explained by the upregulation of S100A8/A9.

399

400

401 **Discussion**

402

403 Normal mammary epithelial cells are closest neighboring cells to malignant epithelial
404 cells during the initial process of carcinogenesis. Also, cancer cells often contact
405 adjacent normal epithelial cells during the invasion process. The underlying hypothesis
406 of our work was that normal epithelial cells adjacent to cancer cells may undergo
407 molecular and functional transition despite the normal microscopic appearance. Indeed,
408 we observed that non-tumorigenic epithelial cells undergo a substantial molecular and
409 phenotypic changes when the cells were directly exposed to the breast cancer cells.
410 Non-tumorigenic mammary epithelial MCF10A cells showed significant increase in cell
411 proliferation and migration when they were directly co-cultured with breast cancer cells.
412 Along with the changes in cell behavior, directly co-cultured MCF10A cells also
413 exhibited spindle-shaped morphologies and significant downregulation of epithelial
414 adhesion markers such as E-cadherin and Zo-1. Previous studies have shown that E-
415 cadherin expression in normal epithelial cells plays an important role during the
416 process initial carcinogenesis by regulating cell protrusion formation of neighboring
417 transformed cells [12, 18]. Additionally, three-dimensional direct co-culture with breast
418 cancer cells induced loss of epithelial differentiation features in non-tumorigenic MDCK
419 cells [19]. Finally, Trujillo et al [20] have shown that normal epithelial cells adjacent
420 breast tumors show increased expression of EMT markers such as α-SMA and
421 S100A4. Our data, along with these previous reports, suggests that breast cancer cells
422 may induce epithelial mesenchymal transition in adjacent normal mammary epithelial
423 cells via direct cell-cell contacts.
424 Using the *in vitro* direct co-culture approach, we observed a dynamic and complex cell-
425 cell interactions between breast cancer cells and non-tumorigenic mammary epithelial
426 cells that include diverse physical contacts and vesicle transfers. We were also able to

427 demonstrate that the tumor cells and normal epithelial cells exhibit various physical
428 interactions *in vivo* by showing live images taken from the mouse earlobe model. Such
429 dynamic interactions have also been reported in a three-dimensional co-culture
430 experiment [20] and between various stromal cell types in microenvironment [21].
431 Recently, Roh-Johnson et al [22] have shown that the cytoplasmic transfer during the
432 cell-cell contacts between melanoma cells and macrophages is critical in cancer cell
433 invasion *in vivo*. The clinical and biologic consequences of this cell-cell interactions
434 between malignant cancer cells and adjacent normal epithelial cells are unclear.
435 Normal epithelial cells exert tumor-suppressive effects during the initial phase of
436 carcinogenesis by cell competition and protrusion of neighboring transformed cells [18,
437 23, 24]. Alternatively, tumor cells can reprogram the adjacent normal epithelial cells to
438 form a pro-tumorigenic microenvironment at the late stages of carcinogenesis [13]. This
439 phenomenon of tumor-driven reprogramming of microenvironment has been shown for
440 other cell types such as fibroblast or adipocytes in breast cancer [5, 6]. Further
441 research is needed to clarify the role of molecular transformation of normal epithelial
442 cells during the breast cancer progression.
443 In molecular levels, we observed that S100A8/A9 expression levels are significantly
444 up-regulated when non-tumorigenic MCF10A epithelial cells were co-cultured with
445 MDA-MB-231 cells. The up-regulation of S100A8/A9 was also observed in a syngeneic
446 mouse xenograft model of 4T1 murine mammary carcinoma cells. S100A8/A9 act as
447 alarmins that trigger damage-associated molecular patterns molecules and modulate
448 the immune response [25]. S100A8/A9 overexpression in MCF10A cells resulted in a
449 similar cell phenotype seen in directly co-cultured MCF10A cells in terms of in vitro cell
450 behaviors and cell signaling activities. Moon A and the colleagues have previously
451 shown that S100A8/A9 overexpression can induce phenotype transformation in
452 MCF10AHRAS cells by . Our results show that S100A8/A9, potentially critical

453 regulators of cell behavior, could be induced in non-tumorigenic mammary epithelial
454 cells during the dynamic cell-cell interactions with adjacent breast cancer cells.
455 Additionally, the directly co-cultured and S100A8/A9-overexpressing cells both showed
456 increased phosphorylation of PRAS40-Thr²⁴⁶ and its upstream Akt-Ser⁴⁷³.
457 Phosphorylation of Akt-Ser⁴⁷³ and PRAS40-Thr²⁴⁶ activate mTOR signaling that affects
458 diverse biologic aspects of the epithelial cells and other cells of tumor
459 microenvironment [26-28]. The biologic implications and therapeutic potentials of the
460 observed mTOR signaling dysregulation in mammary epithelial cells in breast cancer
461 microenvironment should be further explored.
462 Our study has several limitations. First, we have used a limited number of cell lines
463 during the present study. The molecular transitions in non-tumorigenic mammary
464 epithelial cells might vary along the different subtypes of breast cancers. Second, the
465 effect of this phenotype changes in mammary epithelial cells on the breast cancer cells
466 in terms of breast cancer growth and metastasis has not been investigated using *in*
467 *vivo* breast cancer models. Finally, although we've demonstrated the up-regulation of
468 S100A8/A9 expression in mouse fatpad xenograft tumors, we were not able to
469 examine the S100A8/A9 up-regulation in human breast cancer tissues. Further studies
470 investigating the biologic consequence and clinical implications of the molecular
471 changes in the non-tumorigenic mammary epithelial cells in breast cancer
472 microenvironment are needed.
473
474

475 **Conclusion**

476

477 In conclusion, our study demonstrate that breast cancer cells may induce substantial
478 molecular changes in non-tumorigenic mammary epithelial cells via dynamic cell-cell
479 interactions. As the results, mammary epithelial cells undergo a phenotype transition
480 which involves more active proliferation and migration. S100A8/A9 may play a pivotal
481 role during this phenotype transition of mammary epithelial cells. Our study provides
482 scientific basis for pursuing a novel therapeutic strategy that targets the non-
483 tumorigenic mammary epithelial cells in tumor microenvironments.

484

485

486

487

488 **Declarations**

489

490 *Ethics approval and consent to participate*

491 This study does not include data on the human subjects. For animal experiments, the
492 fatpad xenograft tumor experiment was approved by the Institutional Animal Care and
493 Use Committee in Seoul National University Hospital (SNUH-IACUC, 17-0165-S1A0
494 (1)), and the *in vivo* imaging experiments were performed in accordance with the
495 Animal Care and Use Committee guidelines of Woosung BSC (Suwon, Korea).

496

497 *Consent for publication*

498 This manuscript does not contain any individual person's data in any form (including
499 individual details, images or videos).

500

501 *Availability of data and materials*

502 Data supporting these results are available from the authors upon request.

503

504 *Competing interests*

505 The authors declare that they have no competing interests.

506

507 *Funding*

508 This work was supported by the Basic Science Research Program through the National
509 Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and
510 Technology (2015R1D1A1A02061904), by the grant from the National R&D Program
511 for Cancer Control, Ministry for Health and Welfare, Republic of Korea (A1520250),
512 and by the grant of the Korea Health Industry Development Institute (KHIDI), funded by
513 the Ministry of Health & Welfare, Republic of Korea (HI13C2148).

514

515 *Authors' contributions*

516 SHJ performed the bulk of the work reported, including writing the initial draft,
517 generating cell lines, and phospho-protein arrays. WHH performed fatpad tumor
518 xenograft studies, PCR, western blotting and writing the initial draft. BSH, JHK
519 performed YP and DSL assisted and provide guidance to cell sorting and animal
520 experiments. NHK and MCP performed *in vivo* cell imaging studies. ESL, HBL, and WH
521 analyzed the transcriptome data and pathway analysis. JC and JIK provided RNA
522 sequencing data of breast cancer and analyzed the target gene expression levels.
523 DYN and HGM initiated the study, provided overall direction and oversight to the
524 project, and finalized the manuscript. All authors read and approved the final
525 manuscript.

526

527 *Acknowledgements*

528 Not applicable.

529

530

531 **References**

532

- 533 1. Joyce JA, Pollard JW: **Microenvironmental regulation of metastasis.** *Nat Rev Cancer* 2009, **9**(4):239-252.
- 534 2. Hanahan D, Coussens LM: **Accessories to the crime: functions of cells recruited to the tumor microenvironment.** *Cancer Cell* 2012, **21**(3):309-322.
- 535 3. Place AE, Jin Huh S, Polyak K: **The microenvironment in breast cancer progression: biology and implications for treatment.** *Breast Cancer Res* 2011, **13**(6):227.
- 536 4. Gajewski TF, Schreiber H, Fu YX: **Innate and adaptive immune cells in the tumor microenvironment.** *Nat Immunol* 2013, **14**(10):1014-1022.
- 537 5. Kalluri R: **The biology and function of fibroblasts in cancer.** *Nat Rev Cancer* 2016, **16**(9):582-598.
- 538 6. Lee J, Hong BS, Ryu HS, Lee HB, Lee M, Park IA, Kim J, Han W, Noh DY, Moon HG: **Transition into inflammatory cancer-associated adipocytes in breast cancer microenvironment requires microRNA regulatory mechanism.** *PLoS One* 2017, **12**(3):e0174126.
- 539 7. Pardoll DM: **The blockade of immune checkpoints in cancer immunotherapy.** *Nat Rev Cancer* 2012, **12**(4):252-264.
- 540 8. Klemm F, Joyce JA: **Microenvironmental regulation of therapeutic response in cancer.** *Trends Cell Biol* 2015, **25**(4):198-213.
- 541 9. Fang H, Declerck YA: **Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.** *Cancer Res* 2013, **73**(16):4965-4977.
- 542 10. Porazinski S, de Navascues J, Yako Y, Hill W, Jones MR, Maddison R, Fujita Y, Hogan C: **EphA2 Drives the Segregation of Ras-Transformed Epithelial**

- 557 **Cells from Normal Neighbors.** *Curr Biol* 2016, **26**(23):3220-3229.
- 558 11. Saitoh S, Maruyama T, Yako Y, Kajita M, Fujioka Y, Ohba Y, Kasai N, Sugama N,
559 Kon S, Ishikawa S *et al*: **Rab5-regulated endocytosis plays a crucial role in**
560 **apical extrusion of transformed cells.** *Proc Natl Acad Sci U S A* 2017,
561 **114**(12):E2327-E2336.
- 562 12. Hogan C, Dupre-Crochet S, Norman M, Kajita M, Zimmermann C, Pelling AE,
563 Piddini E, Baena-Lopez LA, Vincent JP, Itoh Y *et al*: **Characterization of the**
564 **interface between normal and transformed epithelial cells.** *Nat Cell Biol*
565 2009, **11**(4):460-467.
- 566 13. Gudjonsson T, Ronnov-Jessen L, Villadsen R, Rank F, Bissell MJ, Petersen OW:
567 **Normal and tumor-derived myoepithelial cells differ in their ability to**
568 **interact with luminal breast epithelial cells for polarity and basement**
569 **membrane deposition.** *J Cell Sci* 2002, **115**(Pt 1):39-50.
- 570 14. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter
571 D, Hu M, Chin L, Richardson A *et al*: **Molecular characterization of the tumor**
572 **microenvironment in breast cancer.** *Cancer Cell* 2004, **6**(1):17-32.
- 573 15. Mattila PK, Lappalainen P: **Filopodia: molecular architecture and cellular**
574 **functions.** *Nat Rev Mol Cell Biol* 2008, **9**(6):446-454.
- 575 16. Rustom A, Saffrich R, Markovic I, Walther P, Gerdes HH: **Nanotubular**
576 **highways for intercellular organelle transport.** *Science* 2004,
577 **303**(5660):1007-1010.
- 578 17. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H,
579 Omeroglu G, Meterissian S, Omeroglu A *et al*: **Stromal gene expression**
580 **predicts clinical outcome in breast cancer.** *Nat Med* 2008, **14**(5):518-527.
- 581 18. Kajita M, Hogan C, Harris AR, Dupre-Crochet S, Itasaki N, Kawakami K,
582 Charras G, Tada M, Fujita Y: **Interaction with surrounding normal epithelial**

- 583 **cells influences signalling pathways and behaviour of Src-transformed**
584 **cells.** *J Cell Sci* 2010, **123**(Pt 2):171-180.
- 585 19. Ivers LP, Cummings B, Owolabi F, Welzel K, Klinger R, Saitoh S, O'Connor D,
586 Fujita Y, Scholz D, Itasaki N: **Dynamic and influential interaction of cancer**
587 **cells with normal epithelial cells in 3D culture.** *Cancer Cell Int* 2014,
588 **14**(1):108.
- 589 20. Trujillo KA, Heaphy CM, Mai M, Vargas KM, Jones AC, Vo P, Butler KS, Joste
590 NE, Bisoffi M, Griffith JK: **Markers of fibrosis and epithelial to mesenchymal**
591 **transition demonstrate field cancerization in histologically normal tissue**
592 **adjacent to breast tumors.** *Int J Cancer* 2011, **129**(6):1310-1321.
- 593 21. Fong EL, Wan X, Yang J, Morgado M, Mikos AG, Harrington DA, Navone NM,
594 Farach-Carson MC: **A 3D in vitro model of patient-derived prostate cancer**
595 **xenograft for controlled interrogation of in vivo tumor-stromal**
596 **interactions.** *Biomaterials* 2016, **77**:164-172.
- 597 22. Roh-Johnson M, Shah AN, Stonick JA, Poudel KR, Kargl J, Yang GH, di
598 Martino J, Hernandez RE, Gast CE, Zarour LR *et al:* **Macrophage-Dependent**
599 **Cytoplasmic Transfer during Melanoma Invasion In Vivo.** *Dev Cell* 2017,
600 **43**(5):549-562 e546.
- 601 23. Leung CT, Brugge JS: **Outgrowth of single oncogene-expressing cells from**
602 **suppressive epithelial environments.** *Nature* 2012, **482**(7385):410-413.
- 603 24. Kajita M, Fujita Y: **EDAC: Epithelial defence against cancer-cell competition**
604 **between normal and transformed epithelial cells in mammals.** *J Biochem*
605 2015, **158**(1):15-23.
- 606 25. Srikrishna G: **S100A8 and S100A9: new insights into their roles in**
607 **malignancy.** *J Innate Immun* 2012, **4**(1):31-40.
- 608 26. Wiza C, Nascimento EB, Ouwendam DM: **Role of PRAS40 in Akt and mTOR**

- 609 **signaling in health and disease.** *Am J Physiol Endocrinol Metab* 2012,
610 **302**(12):E1453-1460.
- 611 27. Kim LC, Cook RS, Chen J: **mTORC1 and mTORC2 in cancer and the tumor**
612 **microenvironment.** *Oncogene* 2017, **36**(16):2191-2201.
- 613 28. Duluc C, Moatassim-Billah S, Chalabi-Dchar M, Perraud A, Samain R, Breibach
614 F, Gayral M, Cordelier P, Delisle MB, Bousquet-Dubouch MP *et al:*
615 **Pharmacological targeting of the protein synthesis mTOR/4E-BP1**
616 **pathway in cancer-associated fibroblasts abrogates pancreatic tumour**
617 **chemoresistance.** *EMBO Mol Med* 2015, **7**(6):735-753.
- 618
- 619
- 620
- 621
- 622

623 **Figure legends**

624

625 **Figure 1. Dynamic cell-cell interactions between breast cancer cells and non-**
626 **tumorigenic mammary epithelial cells.**

627

628 Representative images of cell-cell interactions between RFP-transfected MDA-MB-231
629 breast cancer cells and GFP-transfected MCF10A non-tumorigenic mammary epithelial
630 cells were captured using time-lapse confocal microscopy (a-d). **a** MDA-MB-231 cells
631 use lamellipodia-like structures to contacting MCF10A cells (yellow arrow) or distant
632 MCF10A cells (white arrow). **b** Nanotube-like structures extending from MDA-MB-231
633 cells are seen (white arrows). **c** RFP-expressing vesicles from MDA-MB-231 cells are
634 transferred to MCF10A cells (white arrows). **d-e** The area within the white rectangle in
635 Figure 1d is shown in 1e. Transferred vesicles from MDA-MB-231 cells are located in
636 both nucleus (white arrow) and cytoplasm (yellow arrow) of MCF10A cells. **f** A minority
637 of co-cultured cells show dual fluorescence. **g** The representative images of the *in vivo*
638 behavior of MDA-MB-231 cells and MCF10A cells co-injected in the earlobe of mouse
639 are shown with migrating extracellular vesicles (white arrows).

640

641 **Figure 2. Phenotype transition of non-tumorigenic mammary epithelial cells**
642 **when directly co-cultured with breast cancer cells.**

643

644 **a** MCF10A cells were directly co-cultured with MDA-MB-231, SK-BR3, and MCF7
645 breast cancer cells. After sorting out the MCF10A cells, the cellular morphologies are
646 shown. **b** The expression levels of epithelial-mesenchymal transition markers were
647 measured by PCR in MCF10A cells after co-culture with MDA-MB-231 cells (upper)
648 and quantified (lower). **c** Relative growth rate of co-cultured MCF10A cells was

649 measured based on ATP level with CellTiter-Glo reagent. **d** The representative images
650 and quantified results of colony-formation assay for co-cultured MCF10A cells are
651 shown. **e** The representative images and quantified results of transwell migration assay
652 for co-cultured MCF10A cells are shown. **f** The representative images and quantified
653 results of 3-dimensional Matrigel culture assay for co-cultured MCF10A cells are shown.
654 Error bars denote mean \pm SD. *P < 0.05, **P < 0.01, ***P < 0.001. P values are
655 determined by the Mann-Whitney test.

656

657 **Figure 3. Transcriptomic and proteomic profiles of non-tumorigenic mammary**
658 **epithelial cells co-cultured with breast cancer cells.**

659

660 **a** Heatmap shows the top 60 genes that were up- or down-regulated in MCF10A cells
661 co-cultured with MDA-MB-231 cells. **b** Heatmap shows the significant enrichment of
662 KEGG pathways based on the RNA sequencing data. Pathways significantly
663 dysregulated in both datasets are listed on the right side. **c** Results of phosphor-protein
664 array experiments are shown. Spots with more than two-fold changes are marked with
665 numbered rectangles and listed below (upper). The overall quantification results of
666 phospho-protein array are shown (lower).

667

668 **Figure 4. S100A8/A9 up-regulation in breast cancer tissues and**
669 **microenvironments.**

670

671 **a** S100A8/A9 mRNA levels and protein levels in MCF10A cells co-cultured with MDA-
672 MB-231 cells are shown. **b** The S100A8/A9 mRNA levels extracted from human breast
673 cancer RNA sequencing data are shown. **c** S100A8/A9 mRNA levels in breast cancer
674 stromal tissues are shown (Finak et al. GSE9014). **d** Mouse mammary fatpad tissues

675 bearing 4T1 breast cancer cells were stained against S100A8 and S100A9. Lower
676 panels show magnified images of the upper insets. **e** Non-tumor-bearing mouse fatpad
677 were stained with S100A8 and S100A9. *P < 0.05, **P < 0.01, ***P < 0.001. P values are
678 determined by the unpaired Student t-test.



679

680 **Figure 5. S100A8/A9-overexpression induce the phenotypes of non-tumorigenic**
681 **mammary epithelial cells co-cultured with breast cancer cells.**

682


683 **a** Relative growth rate of S100A8/A9-overexpressing MCF10A cells was determined
684 based on ATP level with CellTiter-Glo reagent. **b** The representative images and
685 quantified results of transwell migration assay for S100A8/A9-overexpressing MCF10A
686 cells are shown. **c** The representative images and quantified results of Matrigel
687 invasion assay for S100A8/A9-overexpressing MCF10A cells are shown. **d** The
688 representative images and quantified results of colony-formation assay for S100A8/A9-
689 overexpressing MCF10A cells are shown. **e-f** Results of phosphor-protein array
690 experiments with S100A8/A9-overexpressing MCF10A cells (e) and quantified
691 expression of significantly dysregulated proteins (f) are shown. **g** The comparison of
692 phospho-protein array patterns for co-cultured MCF10A cells and S100A8/A9-
693 overexpressing MCF10A cells are shown. For example, 'Down/Up' designates spots
694 that are down-regulated in co-cultured MCF10A cells and up-regulated in S100A8/A9-
695 overexpressing MCF10A cells, respectively. **h** Western blotting results showing the
696 protein expression levels of selected dysregulated proteins in both co-cultured
697 MCF10A cells and S100A8/A9-overexpressing MCF10A cells. Error bars denote mean
698 \pm SD. **P < 0.01, ***P < 0.001. P values are determined by the Mann-Whitney test.

699




a


MCF10A (Control)




MCF10A (c/c MDA-MB-231)





MCF10A (c/c SK-BR3)






MCF10A (c/c MCF7)

**b**



MCF10A:MDA-MB-231 ratio

**e**


MCF10A Control MCF10A (c/c MDA-MB-231)

**c****d**


MCF10A Control MCF10A (c/c MDA-MB-231)

**e**



MCF10A Control MCF10A (c/c MDA-MB-231)




**f**



MCF10A (control)



MCF10A (c/c MDA-MB-231)

■ MCF10A (Control)
■ MCF10A (c/c MDA-MB-231)

a**b****c**

a**b****S100A9****S100A8**

800

600

400

200

0

Normal Tumor

2000

1500

1000

500

0

Normal Tumor

S100A8 S100A9





10.0

5.0

0.0

-5.0

Normal Tumor Normal Tumor

d**e**